Cetuximab associated dermal filler reaction

Abstract

A 52-year-old male patient with hyaluronic acid-based dermal fillers injected in his cheeks was diagnosed with glossotonsillary malignancy, and managed with concurrent cetuximab (epidermal growth factor receptor inhibitor) and radiation therapy. He developed significant inflammation around the dermal filler sites after first cycle of cetuximab which improved with dissolution of the dermal fillers with hyaluronidase. This suggests that cetuximab can lead to inflammation around the dermal filler sites, which can be treated with dissolution of the filler.

The art of prevention: COVID-19 vaccine preparedness for the dermatologist

“…American Society of Plastic Surgeons., 2018 , Food and Drug Administration, 2020 , Pathmanathan and Dzienis, 2019 , Zhang, Rachel. “FDA Presentation and Voting Questions”.…”

The 10-Point Plan 2021: Updated Concepts for Improved Procedural Safety During Facial Filler Treatments

“…Carbohydrates preferentially bind to membrane receptors such as immunoglobulins to induce clustering and primary B cell activation, stimulating production of low affinity, short-living IgM, and no induction of memory effect in the absence of T cells. 52,53 Conversely, bacteria act as potent activators of the TLRs (1,4,5,7,9) to induce inflammation, innate immunity, and non-agent-specific autoimmunity (Table 8). This underlines the critical importance of aseptic technique in avoiding late-onset inflammatory and immune sequelae.…”

“…Immune checkpoint inhibitors (ICI) 6 remove the brake on activated T-lymphocytes, enabling T-cell attack on normal cells. LOAEs are documented after ipilimumab 7 , 8 and cetuximab, 9 and facial swelling and granulomatous reactions with protein-tyrosine kinase inhibitors. However, uneventful HA filler treatment has been described after treatment with imatinib mesylate.…”